Belimumab - GlaxoSmithKline/MedImmune

Drug Profile

Belimumab - GlaxoSmithKline/MedImmune

Alternative Names: Anti-BLyS monoclonal antibody; Benlysta; BmAb; GSK1550188; HGS-1006; LymphoStat-B

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cambridge Antibody Technology; Human Genome Sciences
  • Developer Assistance Publique Hopitaux de Paris; Cancer Trials Australia; GlaxoSmithKline; Hospital for Special Surgery; Human Genome Sciences; North Shore-Long Island Jewish Health System; University of Pennsylvania
  • Class Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Systemic lupus erythematosus
  • Phase III Anti-neutrophil cytoplasmic antibody-associated vasculitis; Lupus nephritis
  • Phase II/III Myositis
  • Phase II Membranous glomerulonephritis; Myasthenia gravis; Renal transplant rejection; Sjogren's syndrome; Systemic scleroderma
  • No development reported Waldenstrom's macroglobulinaemia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 09 Mar 2018 Phase-III clinical trials in Systemic lupus erythematosus (Combination therapy) in Netherlands, USA (SC) (NCT03312907) (EudraCT2016-003050-32)
  • 28 Feb 2018 GlaxoSmithKline completes an expanded access for Systemic lupus erythematosus in USA before February 2018 (NCT03125486)
  • 13 Nov 2017 Registered for Systemic lupus erythematosus (Adjunctive treatment, Treatment-experienced) in Iceland, Norway, Liechtenstein, European Union (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top